Clinical trial

PF-07104091 as a Single Agent and in Combination Therapy

NCT04553133

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2020-09-16

PhasePHASE2

Study timeline

Study start (actual)2020-09-16Date precision: day

Registry last updated2026-05-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Small Cell Lung Cancerunresolved

Ovarian Cancerunresolved

Breast Cancerunresolved

Interventions

PF-07104091 monotherapy dose escalationDRUG

PF-07104091 + palbociclib + fulvestrantDRUG

PF-07104091 + palbociclib + letrozoleDRUG

PF-07104091 monotherapy dose expansion (ovarian)DRUG

PF-07104091 monotherapy dose expansion (SCLC)DRUG

PF-07104091 + Fulvestrant (post CDK4/6)DRUG

PF-0704091 + Fulvestrant (post CDK4/6)DRUG

Sponsors & collaborators

Pfizerlead sponsor

Mapped research locations

LouisvilleKentucky, United States5 Des MoinesIowa, United States3 New YorkNew York, United States2 BostonMassachusetts, United States1 ShanghaiShanghai Municipality, China1 CharlottesvilleVirginia, United States1 PlovdivBulgaria1 TianjinTianjin Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04553133 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.